#cancer #CRISPR
June 2025:
"Some biotechnology companies have an answer: alter T cells inside the body instead. Treatments that deliver a gene for the CAR protein to cells in the blood could be mass produced and available on demand — theoretically, at a much lower price than current CAR-T therapies. A single dose of commercial CAR-T therapy costs around $500,000. A vial of in vivo treatment might cost an order of magnitude less.
The idea has some high-profile proponents. The founders of Capstan Therapeutics, a company in San Diego, California, that is focused exclusively on in vivo cell therapies, include CAR-T pioneers Levine and Carl June, as well as Drew Weissman, who won a Nobel prize for his work on messenger RNA vaccines. CRISPR–Cas9 pioneer and Nobel prizewinner Jennifer Doudna has co-founded a separate company, Azalea Therapeutics in Berkeley, California, that is developing in vivo CAR T. And big pharma is taking notice. In March, the biopharmaceutical firm AstraZeneca agreed to pay up to $1 billion for the Belgium-based in vivo CAR-T company EsoBiotec, which launched its first human trial of an in vivo CAR-T therapy in January."
https://www.nature.com/articles/d41586-025-01570-6